005690.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 05:28):

Stats
Dzisiejszy wolumen	90 998.00
Średni wolumen	703 858
Kapitalizacja rynkowa	349.82B
EPS	KRW0 ( 2024-02-12 )
Następna data zysków	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW11.67 (0.20%)

Wolumen Korelacja

Długi: -0.05 (neutral)

Krótki: -0.23 (neutral)

Signal:(41.47) Neutral

Pharmicell Co., Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharmicell Co., Ltd. Korelacja - Waluta/Towar

-0.52
( weak negative )

-0.51
( weak negative )

0.57
( weak )

-0.58
( weak negative )

-0.08
( neutral )

0.46
( neutral )

Pharmicell Co., Ltd. Finanse

Annual	2023
Przychody:	KRW56.23B
Zysk brutto:	KRW14.96B (26.60 %)
EPS:	KRW59.63

FY	2023
Przychody:	KRW56.23B
Zysk brutto:	KRW14.96B (26.60 %)
EPS:	KRW59.63

FY	2022
Przychody:	KRW60.18B
Zysk brutto:	KRW23.82B (39.58 %)
EPS:	KRW137.79

FY	2021
Przychody:	KRW50.89B
Zysk brutto:	KRW23.46B (46.09 %)
EPS:	KRW158.70

Financial Reports:

No articles found.

Pharmicell Co., Ltd.

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.